FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Ostertag Eric  (Last) (First) (Middle)  C/O POSEIDA THERAPEUTICS, INC.  9390 TOWNE CENTRE DRIVE, STE 200					Issuer Name and Ticker or Trading Symbol     Poseida Therapeutics, Inc. [ PSTX ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director X 10% Owner  V Officer (give title Other (specify)					
				0	3. Date of Earliest Transaction (Month/Day/Year) 04/01/2021									Chief Executive Officer					
(Street) SAN DIEGO CA 92121				_   4	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting					
(City) (State) (Zip)														Person					
		Table	I - Non-Deri	vativ	/e S	ecurities	Acq	uired,	_					<del>-</del>					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/		2A. Deemed Execution Date, if any (Month/Day/Year)		Cod	Transaction Code (Instr.		4. Securities Acquired Disposed Of (D) (Instr.		red (A) or str. 3, 4 and 5)		5. Amount Securities Beneficial Owned Following	ies ially ng	Form (D) or Indire	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Cod	Code V		nount (A) or (D) Price			Transac	Reported Transaction(s) (Instr. 3 and 4)					
Common Sto	ock		04/01/20	21			S	1)	2	9,834	D	\$9.	5544 <sup>(2)</sup>	3,88	32,383		I	See footnote <sup>(3)</sup>	
Common Sto	ock		04/05/20	21			S	1)	2	8,549	D	\$9.	625(4)	3,85	53,834		I	See footnote <sup>(3)</sup>	
Common Sto	ock		04/05/20	21			S	1)	1	,617	D	\$10.	3219 <sup>(5</sup>	3,85	52,217		I	See footnote <sup>(3)</sup>	
Common Sto	ock		04/01/20	21			S	1)	2	7,347	D	\$9.	5544 <sup>(2)</sup>	3,56	50,277		I	See footnote <sup>(6)</sup>	
Common Sto	ock		04/05/20	21			S	1)	2	6,170	D	\$9.	625(4)	3,53	34,107		I	See footnote <sup>(6)</sup>	
Common Sto	ock		04/05/20	21			S	1)	1	,483	D	\$10.	3219 <sup>(5</sup>	3,53	32,624		I	See footnote <sup>(6)</sup>	
Common Sto	ock													542	2,985		D		
Common Sto	ock													629	9,194		I	See footnote <sup>(7)</sup>	
Common Sto	ock													96:	1,445	I		See footnote	
Common Stock													200,696			I	See footnote <sup>(8)</sup>		
		Ta	ble II - Deriva (e.g., ı			curities . Ils, warra								/ Owne	d	,			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)			3A. Deemed Execution Date, if any (Month/Day/Year	4. Tra	4. 5. Nur Transaction of Code (Instr. Deriva		mber /ative irities ired r osed ) r. 3, 4	6. Date Expirati	Exercion Da	Exercisable and		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		s. Price of Derivative Security Instr. 5)	derivativ Securitie Beneficia Owned Followin Reported	Following Reported Transaction(s)		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode	V (A)	(D)	Date Exercis	able	Expiration Date	on Tit	or Nu of	ount						

## Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2020.
- 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.21 to \$10.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
- 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.28 to \$10.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$10.28 to \$10.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

- 6. The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- 7. The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
- 8. The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.

## Remarks

/s/ Johanna Mylet, Attorneyin-Fact 04/05/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.